Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Diagnosis of systemic lupus erythematosis (SLE) by the American College of Rheumatology (ACR) Criteria.~History of a positive antinuclear antibody (ANA) test result at any time in the past.~40 participants with history of mild to moderate SLE disease Minimally active or inactive SLE disease, i.e., (Safety of Estrogens in Lupus Erythematosis National Assessment (SELENA) Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), SELENA-SLEDAI ≤2 at the start of the study.~Age ≥ 18 years and ≤ 50 years. Gender: females Ability to provide informed consent. Maintenance Prednisone dose ≤ 15 mg/day. Plaquenil ≤ 400 mg/day.~Exclusion Criteria:~Hypersensitivity to any vaccine component Active infections including but not limited to human immunodeficiency virus (HIV positive), Hepatitis B or C, tuberculosis.~Positive purified protein derivative (PPD) test results without evidence of prior treatment or administration of bacilli Calmette-Guerin (BCG) vaccine. A positive PPD is defined as ≥ 5 mm induration 24-38 hours after receiving 5TU (TU=tuberculin units) of PPD.~Pregnancy or desire to become pregnant during the study period. Breast feeding. Inability to complete the immunization series. Received any blood product or component in the previous 6 months before enrollment.~Received any inactivated vaccine product within 14 days before enrollment. Received any live vaccine product within 21 days before enrollment.~Fever (temperature \> 100°F) at the time of enrollment. Inability to provided informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Gardasil (Type: EXPERIMENTAL): 0.5 ml single dose Gardasil vaccine given at three separate visits

Based on this trial design, predict the completion outcome and termination type (if applicable).